Skip to main content

Table 1 Changes in demographic and clinical characteristics over 5-year

From: Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study

 Baseline (n = 60)5 years (n = 60)Change (n = 60)P value
Demographic characteristics
 Female, N (%)27 (45.0)   
 Smokers, N (%)13 (21.7)   
 Age, year51.9 ± 8.9   
 BMI25.4 ± 4.325.8 ± 4.50.46 ± 1.90.060
 Height (cm)163.6 ± 8.5163.0 ± 8.4−0.57 ± 1.30.002
 Weight (kg)68.2 ± 14.368.8 ± 14.00.62 ± 5.10.345
Disease-specific characteristics
 Duration of psoriasis (year)18.7 ± 16.7
 Duration of PsA (year)14.3 ± 6.9
 Juxta-articular new bone formation29 (48.3)
 Polyarticular21 (35.0)
 Oligoarticular17 (28.3)
 Presence of enthesitis13 (21.7)
 Presence of dactylitis8 (13.3)
 Tender joint at MCP28 (13.3)
 Tender joint at MCP34 (6.6)
 Swollen joint at MCP23 (5.0)
 Swollen joint at MCP32 (3.3)
 CRP (mg/L)4.4 ± 4.94.0 ± 5.2−0.4 ± 5.70.629
 ESR (mm/h)19.0 ± 15.927.5 ± 17.48.7 ± 13.30.000
 DAPSA11.4 ± 9.39.7 ± 5.9−1.7 ± 9.00.150
 PASI6.3 ± 8.64.7 ± 6.4−1.6 ± 7.20.088
 HAQ0.3 ± 0.40.4 ± 0.50.1 ± 0.40.067
 MASES0.9 ± 2.40.5 ± 1.4−0.5 ± 1.80.035
 VAS pain (mm)31.1 ± 26.131.1 ± 24.50 ± 26.41.000
 VAS PhyGA (mm)23.8 ± 18.918.5 ± 18.2−5.4 ± 21.80.060
 VAS PatGA (mm)41.0 ± 28.337.0 ± 22.9−4.0 ± 26.00.243
 Tender joint count2.9 ± 5.71.8 ± 2.8−1.2 ± 5.40.103
 Swollen joint count0.8 ± 1.50.7 ± 1.6−0.1 ± 1.70.597
 Deformed joint count3.8 ± 6.47.0 ± 7.43.2 ± 5.50.000
Current/ever treatment
 NSAIDs, N (%)25 (41.7)28 (46.7) 0.080
 Corticosteroids, N (%)3 (5.0)4 (6.7)1.000
 csDMARDs, N (%)44 (73.3)49 (81.7)0.274
 bDMARDs, N (%)16 (26.7)23 (35.3)0.172
 Any DMARDs, N (%)46 (76.7)53 (88.3)0.093
 csDMARDs + bDMARDs, N (%)16 (26.7)19 (31.7)0.547
Clinical response
 VLDA, N (%)4 (6.7)8 (13.3) 0.083
 MDA, N (%)15 (25.0)22 (36.7)0.166
 REM (DAPSA ≤4), N (%)14 (23.3)13 (21.7)0.044
 LDA (DAPSA ≤14), N (%)26 (43.3)29 (48.3)
 MDA (DAPSA ≤28), N (%)17 (28.3)18 (30.0)
 HDA (DAPSA >28), N (%)3 (5.0)0 (0)
  1. Results are mean ± SD or number (percentage) unless otherwise indicated. Significant results are highlighted in italics
  2. BMI body mass index, MCP metacarpophalangeal joint, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAPSA Disease Activity in PSoriatic Arthritis, PASI Psoriasis Area and Severity Index, HAQ Health Assessment Questionnaire, VAS Visual Analogue Scale, PhyGA Physician Global Assessment, PatGA Patient Global Assessment, NSAIDs non-steroidal anti-inflammatory drugs, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs biologic disease-modifying anti-rheumatic drugs, VLDA very low disease activity, MDA minimal disease activity, REM remission, LDA low disease activity, MDA moderate disease activity, HDA high disease activity